| MeSH term | MeSH ID | Detail |
|---|---|---|
| Melanoma | D008545 | 69 associated lipids |
| Leukemia | D007938 | 74 associated lipids |
| Pancreatic Neoplasms | D010190 | 77 associated lipids |
| Prostatic Neoplasms | D011471 | 126 associated lipids |
| Colonic Neoplasms | D003110 | 161 associated lipids |
| Lung Neoplasms | D008175 | 171 associated lipids |
| Body Weight | D001835 | 333 associated lipids |
MAYTANSINE
MAYTANSINE is a lipid of Polyketides (PK) class. Maytansine is associated with abnormalities such as Myelosuppression and BOSLEY-SALIH-ALORAINY SYNDROME. The involved functions are known as Mutation, Agent, Polymerization, Cell Cycle Arrest and Drug Kinetics. Maytansine often locates in Cytoplasm, Hepatic, Lysosomes, Cell surface and Microtubules. The associated genes with MAYTANSINE are ABCB1 gene, HM13 gene, CNN1 gene, CYP2C8 gene and CYP2D6 gene. The related lipids are Valerates. The related experimental models are Xenograft Model.
Cross Reference
Introduction
To understand associated biological information of MAYTANSINE, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with MAYTANSINE?
MAYTANSINE is suspected in Myelosuppression, BOSLEY-SALIH-ALORAINY SYNDROME and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with MAYTANSINE
PubChem Associated disorders and diseases
What pathways are associated with MAYTANSINE
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with MAYTANSINE?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with MAYTANSINE?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with MAYTANSINE?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with MAYTANSINE?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with MAYTANSINE?
Xenograft Model
Xenograft Model are used in the study 'IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors.' (Ab O et al., 2015).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with MAYTANSINE
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Weiler D et al. | Rapid response to trastuzumab emtansine in a patient with HER2-driven lung cancer. | 2015 | J Thorac Oncol | pmid:25789838 |
| Krop IE et al. | Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer. | 2015 | J. Clin. Oncol. | pmid:25713436 |
| Marcoux J et al. | Native mass spectrometry and ion mobility characterization of trastuzumab emtansine, a lysine-linked antibody drug conjugate. | 2015 | Protein Sci. | pmid:25694334 |
| Goldmacher VS et al. | High-affinity accumulation of a maytansinoid in cells via weak tubulin interaction. | 2015 | PLoS ONE | pmid:25671541 |
| Nicoletti R et al. | T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2. | 2015 | Clin. Exp. Metastasis | pmid:25398397 |
| Uppal H et al. | Potential mechanisms for thrombocytopenia development with trastuzumab emtansine (T-DM1). | 2015 | Clin. Cancer Res. | pmid:25370470 |
| Krop IE et al. | Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA. | 2015 | Ann. Oncol. | pmid:25355722 |
| Widdison WC et al. | Development of Anilino-Maytansinoid ADCs that Efficiently Release Cytotoxic Metabolites in Cancer Cells and Induce High Levels of Bystander Killing. | 2015 | Bioconjug. Chem. | pmid:26355774 |
| Cosmai L et al. | Renal toxicity of anticancer agents targeting HER2 and EGFR. | 2015 | J. Nephrol. | pmid:26341657 |
| Bartsch R et al. | Activity of T-DM1 in Her2-positive breast cancer brain metastases. | 2015 | Clin. Exp. Metastasis | pmid:26303828 |
| Michel LL et al. | T-DM1 as a New Treatment Option for Patients with Metastatic HER2-positive Breast Cancer in Clinical Practice. | 2015 | Anticancer Res. | pmid:26254411 |
| Piwko C et al. | Safety Profile and Costs of Related Adverse Events of Trastuzumab Emtansine for the Treatment of HER2-Positive Locally Advanced or Metastatic Breast Cancer Compared to Capecitabine Plus Lapatinib from the Perspective of the Canadian Health-Care System. | 2015 | Clin Drug Investig | pmid:26123628 |
| Hayashi T et al. | Targeting HER2 with T-DM1, an Antibody Cytotoxic Drug Conjugate, is Effective in HER2 Over Expressing Bladder Cancer. | 2015 | J. Urol. | pmid:26047983 |
| Shen BQ et al. | Non-Clinical Disposition and Metabolism of DM1, a Component of Trastuzumab Emtansine (T-DM1), in Sprague Dawley Rats. | 2015 | Drug Metab Lett | pmid:26031461 |
| Kan S et al. | Gemcitabine treatment enhances HER2 expression in low HER2-expressing breast cancer cells and enhances the antitumor effects of trastuzumab emtansine. | 2015 | Oncol. Rep. | pmid:25976081 |
| Dholaria B and Srinivasan S | T-DM1-related carotenoderma and hand-foot syndrome. | 2015 | Lancet | pmid:25933279 |
| Van den Mooter T et al. | Trastuzumab emtansine in advanced human epidermal growth factor receptor 2-positive breast cancer. | 2015 | Expert Opin Biol Ther | pmid:25865453 |
| Hong EE et al. | Design of Coltuximab Ravtansine, a CD19-Targeting Antibody-Drug Conjugate (ADC) for the Treatment of B-Cell Malignancies: Structure-Activity Relationships and Preclinical Evaluation. | 2015 | Mol. Pharm. | pmid:25856201 |
| Widdison W et al. | Metabolites of antibody-maytansinoid conjugates: characteristics and in vitro potencies. | 2015 | Mol. Pharm. | pmid:25826705 |
| Mang Y et al. | Efficient elimination of CD103-expressing cells by anti-CD103 antibody drug conjugates in immunocompetent mice. | 2015 | Int. Immunopharmacol. | pmid:25467246 |
| Kalsi R et al. | Brain metastasis and response to ado-trastuzumab emtansine: a case report and literature review. | 2015 | Clin. Breast Cancer | pmid:25454740 |
| Sibaud V et al. | T-DM1-related telangiectasias: a potential role in secondary bleeding events. | 2015 | Ann. Oncol. | pmid:25403586 |
| Yamamoto H et al. | Phase I and pharmacokinetic study of trastuzumab emtansine in Japanese patients with HER2-positive metastatic breast cancer. | 2015 | Jpn. J. Clin. Oncol. | pmid:25332421 |
| Singh JC and Lichtman SM | Targeted Agents for HER2-Positive Breast Cancer: Optimal Use in Older Patients. | 2015 | Drugs Aging | pmid:26645293 |
| Hamblett KJ et al. | SLC46A3 Is Required to Transport Catabolites of Noncleavable Antibody Maytansine Conjugates from the Lysosome to the Cytoplasm. | 2015 | Cancer Res. | pmid:26631267 |
| Whiteman KR et al. | Lorvotuzumab mertansine, a CD56-targeting antibody-drug conjugate with potent antitumor activity against small cell lung cancer in human xenograft models. | 2014 Mar-Apr | MAbs | pmid:24492307 |
| Tanz R et al. | [Towards an integrated approach to cardiovascular toxicities related to the treatments of breast cancer]. | 2014 Jul-Aug | Bull Cancer | pmid:25091656 |
| Panowski S et al. | Site-specific antibody drug conjugates for cancer therapy. | 2014 Jan-Feb | MAbs | pmid:24423619 |
| Beck A and Reichert JM | Antibody-drug conjugates: present and future. | 2014 Jan-Feb | MAbs | pmid:24423577 |
| Lieberman P and Castells M | Desensitization to chemotherapeutic agents. | 2014 Jan-Feb | J Allergy Clin Immunol Pract | pmid:24565784 |
| Perrino E et al. | Curative properties of noninternalizing antibody-drug conjugates based on maytansinoids. | 2014 | Cancer Res. | pmid:24520075 |
| Kümler I et al. | A systematic review of dual targeting in HER2-positive breast cancer. | 2014 | Cancer Treat. Rev. | pmid:24080156 |
| Berdeja JG | Lorvotuzumab mertansine: antibody-drug-conjugate for CD56+ multiple myeloma. | 2014 | Front Biosci (Landmark Ed) | pmid:24389179 |
| Wang J et al. | Exposure-response relationship of T-DM1: insight into dose optimization for patients with HER2-positive metastatic breast cancer. | 2014 | Clin. Pharmacol. Ther. | pmid:24488143 |
| Lianos GD and Roukos DH | From linear 'dogma' and trastuzumab-emtansine to future transcriptional circuitry-based drug discovery for breast cancer. | 2014 | Future Oncol | pmid:24490597 |
| Yan M et al. | HER2 aberrations in cancer: implications for therapy. | 2014 | Cancer Treat. Rev. | pmid:24656976 |
| Thery JC et al. | Resistance to human epidermal growth factor receptor type 2-targeted therapies. | 2014 | Eur. J. Cancer | pmid:24462377 |
| Amiri-Kordestani L et al. | FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. | 2014 | Clin. Cancer Res. | pmid:24879797 |
| Stinchcombe TE | Novel formulations and new mechanisms of delivering chemotherapy. | 2014 | Am Soc Clin Oncol Educ Book | pmid:24857128 |
| Golfier S et al. | Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect. | 2014 | Mol. Cancer Ther. | pmid:24714131 |
| Diessner J et al. | Targeting of preexisting and induced breast cancer stem cells with trastuzumab and trastuzumab emtansine (T-DM1). | 2014 | Cell Death Dis | pmid:24675467 |
| Carlson JA et al. | Trastuzumab emtansine and stereotactic radiosurgery: an unexpected increase in clinically significant brain edema. | 2014 | Neuro-oncology | pmid:24497407 |
| Kusari S et al. | Endophytes are hidden producers of maytansine in Putterlickia roots. | 2014 | J. Nat. Prod. | pmid:25478947 |
| Kim MT et al. | Statistical modeling of the drug load distribution on trastuzumab emtansine (Kadcyla), a lysine-linked antibody drug conjugate. | 2014 | Bioconjug. Chem. | pmid:24873191 |
| Kolarich AR et al. | Ado-trastuzamab emtansine associated hyponatremia and intracranial hemorrhage. | 2014 | Acta Oncol | pmid:24834794 |
| Dhillon S | Trastuzumab emtansine: a review of its use in patients with HER2-positive advanced breast cancer previously treated with trastuzumab-based therapy. | 2014 | Drugs | pmid:24659374 |
| Patel KC et al. | Ado-trastuzumab emtansine for the treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer. | 2014 | Am J Health Syst Pharm | pmid:24644113 |
| Diéras V and Bachelot T | The success story of trastuzumab emtansine, a targeted therapy in HER2-positive breast cancer. | 2014 | Target Oncol | pmid:23852665 |
| Boku N | HER2-positive gastric cancer. | 2014 | Gastric Cancer | pmid:23563986 |
| Gao Y et al. | Enhancement of ansamitocin P-3 production in Actinosynnema pretiosum by a synergistic effect of glycerol and glucose. | 2014 | J. Ind. Microbiol. Biotechnol. | pmid:24174216 |